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Abstract
Background: Focal cortical dysplasia type IIb (FCD IIb) and tuberous sclerosis complex (TSC) are well-recognized
causes of chronic intractable epilepsy in children. Accumulating evidence suggests that activation of the
microglia/macrophage and concomitant inflammatory response in FCD IIb and TSC may contribute to the
initiation and recurrence of seizures. The membrane glycoproteins CD47 and CD200, which are highly expressed in
neurons and other cells, mediate inhibitory signals through their receptors, signal regulatory protein α (SIRP-α) and
CD200R, respectively, in microglia/macrophages. We investigate the levels and expression pattern of CD47/
SIRP-α and CD200/CD200R in surgically resected brain tissues from patients with FCD IIb and TSC, and the
potential effect of soluble human CD47 Fc and CD200 Fc on the inhibition of several proinflammatory
cytokines associated with FCD IIb and TSC in living epileptogenic brain slices in vitro. The level of interleukin-4 (IL-4),
a modulator of CD200, was also investigated.
Methods: Twelve FCD IIb (range 1.8–9.5 years), 13 TSC (range 1.5–10 years) patients, and 6 control cases (range
1.5–11 years) were enrolled. The levels of CD47/SIRP-α and CD200/CD200R were assessed by quantitative real-time
polymerase chain reaction and western blot. The expression pattern of CD47/SIRP-α and CD200/CD200R was
investigated by immunohistochemical analysis, and the cytokine concentrations were measured by enzyme-linked
immune-sorbent assays.
Results: Both the messenger RNA and protein levels of CD47, SIRP-α, and CD200, as well as the mRNA level of IL-4,
were downregulated in epileptogenic lesions of FCD IIb and TSC compared with the control specimens, whereas
CD200R levels were not significantly changed. CD47, SIRP-α, and CD200 were decreasingly expressed in
dysmorphic neuron, balloon cells, and giant cells. CD47 Fc and CD200 Fc could inhibit IL-6 release but did
not suppress IL-1β or IL-17 production.
Conclusions: Our results suggest that microglial activation may be partially caused by CD47/SIRP-α- and CD200/
CD200R-mediated reductions in the immune inhibitory pathways within FCD IIb and TSC cortical lesions where
chronic neuroinflammation has been established. Upregulation or activation of CD47/SIRP-α and CD200/CD200R
may have therapeutic potential for controlling neuroinflammation in human FCD IIb and TSC.
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Background
Malformations of cortical development (MCD) are major
causes of intractable pediatric epilepsy [1]. Focal cortical
dysplasia (FCD) and tuberous sclerosis complex (TSC)
are two common classes of MCD [2]. FCD is character-
ized by sporadic architectural and cytoarchitectural mal-
formations of the cerebral cortex and has been currently
classified into type I, type II, type III, and additional sub-
types. FCD type II is composed of type IIa (cortical dysla-
mination and dysmorphic neurons) and type IIb (cortical
dyslamination, dysmorphic neurons, and balloon cells) [3].
TSC is an autosomal dominant disorder caused by muta-
tions in the TSC1 or TSC2 genes and is associated with
lesions in multiple organ systems, including cortical tubers
in the brain [4]. In addition to having progressive and
recurrent seizures in common, TSC cortical tubers also
have a number of histopathological features similar to
focal cortical dysplasia type IIb (FCD IIb), such as disorga-
nized lamination, dysmorphic neurons, and giant cells,
suggesting common mechanisms responsible for struc-
tural abnormalities and epileptogenesis [5]. Additionally,
mammalian target of rapamycin complex 1 activation and
autophagy defect are observed in both the TSC giant cells
and FCD IIb balloon cells [6, 7]. And both TSC and FCD
IIb cortical lesions express abnormally phosphorylated tau
protein, an important microtubule-associated protein that
in aging adults produces dementia but in immature brain
interferes with cellular lineage, neuroblast polarity and
migration, and especially cellular growth and morphogen-
esis, features they share with hemimegalencephaly [8, 9].
Although many studies have indicated that seizures are
likely to originate within the dysplastic cortical lesions in
FCD IIb and the cortical tubers in TSC [5], the cellular
and molecular mechanisms underlying the epileptogenesis
of FCD IIb and TSC are still unknown.
Evidence from experimental and clinical studies sug-
gests that activation of immune systems occurs in vari-
ous focal epilepsies and that the inflammatory response
may contribute to the generation and progression of
seizures [10]. Activation of microglia/macrophages, as-
sociated with prominent and sustained overexpression
of proinflammatory mediators, has been described in a
variety of epileptogenic specimens, including FCD IIb
and TSC [11]. As the major immune cells in the central
nervous system (CNS), microglia/macrophages behav-
ior is tightly regulated by the integration of activating
and inhibitory signals [12]. To date, most studies have
focused on the role of the microglial/macrophage acti-
vating pathways and the proinflammatory mediators
released by activated microglia in MCD [13–17]; little
attention has been paid to the expression pattern and
potential effect of microglial/macrophage inhibitory
factors, such as CD47 and CD200. CD47 or integrin-
associated protein is an ubiquitously expressed cell
surface glycoprotein that was originally identified in
association with the integrin αvβ3 [18]. In the CNS,
CD47 is distributed on neurons as well as on other
types of cells, serving as a ligand for signal regulatory
protein α (SIRP-α), an immune inhibitory receptor on
microglia and neurons [19–22]. The interaction between
CD47 and SIRP-α results in the inhibition of microglial/
macrophage phagocytosis [19, 23], and ligation of SIRP-α
by CD47-Fc fusion proteins was found to prevent the
phenotypic and functional maturation of immature den-
dritic cells (DCs) and to inhibit cytokine production by
mature DCs [24]. Another immune inhibitory molecular is
CD200 which is a surface molecule belonging to the im-
munoglobulin supergene family [25]. Similar to CD47,
CD200 is widely expressed in several cells in the CNS, in-
cluding neurons, while its receptor (CD200R) is primarily
present on microglia in the brain [26, 27]. Mice lacking
CD200 display spontaneous microglial activation and have
a more rapid onset of experimental autoimmune enceph-
alomyelitis (EAE), an animal model of multiple sclerosis
(MS) [28]. Similarly, in vitro blockade of CD200R on mac-
rophages leads to elevated release of IL6 and neuronal cell
death in co-cultures with hippocampal neurons expressing
CD200 [29].
In the present study, we investigated the levels and ex-
pression pattern of CD47, SIRP-α, CD200, and CD200R
in surgically resected brain tissues from patients with
FCD IIb and TSC. To assess the potential roles of CD47
and CD200 on the epileptogenesis of FCD IIb and TSC,
we examined the concentrations of several proinflam-
matory cytokines (IL1-β, IL-6, and IL-17), which are as-
sociated with the epileptogenesis of FCD IIb and TSC
[15–17, 30], in living epileptogenic brain slices treated
with soluble recombinant human CD47 Fc chimera
protein or CD200 Fc chimera protein compared with
the vehicle-treated controls. We also evaluated the level
of IL-4, which has been shown to increase the expres-
sion of CD200 [31, 32].
Methods
Subjects
A total of 25 subjects were enrolled: 12 FCD IIb and
13 TSC patients. The cases included in this study were
obtained from the Department of Neurosurgery of the
Xinqiao Hospital (Third Military Medical University,
Chongqing, China). Informed consent and written permis-
sion for all procedures were obtained before surgery from
the patients or their direct relatives. The clinical character-
istics of the patients were summarized in Table 1. All pro-
cedures and experiments were conducted under the
guidelines approved by the Ethics Committee of the Third
Military Medical University, and all investigations were
performed in accordance with the criteria of the Declar-
ation of Helsinki of the World Medical Association.
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Table 1 Clinical features of patients with FCD IIb and TSC
Case no. Gender Age at surgery Diagnosis Seizure focus Epilepsy duration (year) Seizure frequency (per month) Engel’s class Application in the present study
1 F 7 FCD IIb F 5 45 I qPCR, WB, IHC,
2 F 1.8 FCD IIb F 1.2 105 II ELISA
3 M 3.5 FCD IIb T 3 65 I qPCR, WB, IHC,
4 F 7.5 FCD IIb F 6.5 30 I qPCR, WB, IHC,
5 M 5 FCD IIb T 4 80 II ELISA
6 M 4.3 FCD IIb O 3.5 120 I qPCR, WB, IHC,
7 F 9.5 FCD IIb P 8 25 I ELISIA
8 F 5.5 FCD IIb F 4 60 I qPCR, WB, IHC,
9 M 6 FCD IIb P 4.5 35 III qPCR, WB, IHC,
10 F 2 FCD IIb T 1 55 I qPCR, WB, IHC,
11 M 2.3 FCD IIb O 1.3 70 I qPCR, WB, IHC,
12 F 7 FCD IIb T 5.5 30 III ELISA
13 F 6 TSC P 4.8 60 I qPCR, WB, IHC,
14 M 2.1 TSC P 1.2 110 I qPCR, WB, IHC,
15 M 3.9 TSC T 3 82 I qPCR, WB, IHC,
16 F 7 TSC F 5.6 26 II ELISA
17 F 5.5 TSC T 4 48 I ELISA
18 F 4.8 TSC P 3.8 75 I qPCR, WB, IHC,
19 M 10 TSC T 8.1 30 I qPCR, WB, IHC,
20 F 6 TSC F 4.5 25 III ELISIA
21 M 5.5 TSC F 4 31 I qPCR, WB, IHC,
22 M 3 TSC T 2.3 55 I qPCR, WB, IHC,
23 M 1.5 TSC O 0.9 100 III qPCR, WB, IHC,
24 F 4 TSC P 2.9 50 I qPCR, WB, IHC,
25 F 3.5 TSC F 2.6 45 II ELISA
F female, M male, FCD IIb focal cortical dysplasia type IIb, TSC tuberous sclerosis complex, F frontal lobe, O occipital lobe, P parietal lobe, T temporal lobe, ELISA enzyme-linked immune sorbent assay, qPCR quantitative













All epileptogenic tissue samples were obtained from
regions identified as dysplastic by magnetic resonance
imaging and confirmed post hoc by neuropathology. For
the FCD specimens, we followed the current classifica-
tion system of the International League Against Epilepsy
(ILAE) for grading the degree of FCD [3], and only pa-
tients with FCD IIb were included. All diagnoses of TSC
fulfilled the diagnostic criteria for TSC [4]. Furthermore,
clinical mutation analyses of the TSC1 and TSC2 loci
were performed by denaturing high-performance liquid
chromatography (DHPLC) to confirm our diagnoses.
For the control experiments, the histologically nor-
mal cortex tissues were obtained at autopsy from six
control patients (male/female 3/3; mean age 4.83;
range 1.5–11 years), who did not have a history of
seizures or other neurological diseases. All the autop-
sies were performed within 6 h after death. Within
this post-mortem interval, it is well documented that
most proteins are stable and therefore well preserved
[33]. Two neuropathologists also helped to review the aut-
opsy cases, and both gross and microscopic examinations
revealed no structural abnormality.
Tissue processing
Resected brain tissues were immediately divided into two
parts. One portion was immediately placed in a cryovial
that had been soaked in buffered diethylpyrocarbonate
(1:1000) for 24 h and was then snap-frozen in liquid nitro-
gen. Frozen samples were maintained at −80 °C until they
were used for quantitative real-time polymerase chain re-
action (qPCR) and western blot analysis. The second por-
tion of the brain tissue was fixed in 10 % buffered
formalin for 48 h and embedded in paraffin, sectioned at
6 μm for immunohistochemistry (IHC) or 10 μm for
double-labeled immunofluorescence, and mounted on
polylysine-coated slides.
Brain slice preparation
As described previously [34, 35], brain tissue specimens
were resected and immediately submerged in ice-cooled
(0–4 °C), oxygenated (95 % O2 and 5 % CO2) cutting so-
lution containing (in mM) 210 sucrose, 2.5 KCl, 1.02
NaH2PO4, 0.5 CaCl2, 10 MgSO4, 26.19 NaHCO3, and 10
D-glucose, pH 7.4. The specimens were then transferred
rapidly (within 5–10 min) to our laboratory, dissected
into appropriate blocks, and cut into 300 μm thick using
a vibratome (LEICA VT1000S, Leica Microsystem Inc.,
Bannockburn). The slices were then incubated with sol-
uble recombinant human CD47 Fc chimera protein
(Catalogue Number: 4670-CD, R&D Systems) or CD200
Fc chimera protein (Catalogue Number: 2724-CD, R&D
Systems) in a concentration of 5 μg/ml in oxygenated
(95 % O2 and 5 % CO2) artificial cerebrospinal fluid
(ACSF) containing the following (in mM): NaCl, 124;
KCl, 5; NaH2PO4, 1.25; MgSO4, 1.2; NaHCO3, 26; CaCl2,
2; and glucose, 10 (pH 7.4), as CD47 Fc and CD200 Fc
in this dose suppress the production of several inflam-
matory cytokines in human DCs and activated microglia,
respectively [24, 36]. The control slices were incubated
with sterile ACSF which was used for the dilutions of
CD47 Fc and CD200 Fc [37]. All the slices were main-
tained at 37 °C for subsequent cytokine analysis by
enzyme-linked immune-sorbent assays (ELISAs).
Quantitative real-time polymerase chain reaction
Total RNA was isolated from each sample using a TRIzol
reagent isolation kit (Invitrogen, La Jolla, CA), according
to the manufacturer’s instructions. The concentration and
purity of RNA were determined spectrophotometrically at
260/280 nm with a nanodrop spectrophotometer (Ocean
Optics, Dunedin, FL). One microgram of total RNA was
reverse-transcribed into single-stranded complementary
DNA with oligo dT primer (TakaRa, Otsu, Japan). PCR
primers were designed based on the complementary DNA
sequence and synthesized by TaKaRa Biotechnology Com-
pany (Chongqing, China). The primers used were as fol-
lows: CD47 (forward: GAAGATGGATAAGAGTGATGC
TGTC; reverse: ACCTGGGACGAAAAGAATGG), SIRP-
α (forward: GGCTCCTGGTGAATGTATCTGC; reverse:
GTGTTCTCAGCGGCGGTATT), CD200 (forward: GTC
TACCTACAGCCTGGTTTGG; reverse: GCTGGGTAA
TGTTTATCTTGTCCTT), CD200R (forward: ACTAAG
CAAGAATACTGGAGCAATG; reverse: TCAACAACCA
AATGAATCCCAC), and IL-4 (forward: GCTACCCTG
TTCGGCTTTCCT; reverse: TCCCGTGGTTGTCCT
TGTGT). The amplification conditions was as follows:
95 °C for 5 min (1 cycle), followed by 40 cycles of 95 °C
for 30 s, 60 °C for 30 s. The relative quantification of each
product versus the reference gene β-actin was evaluated
by the 2−△△ct method.
Western blot
Equal amounts of protein (60 μg/lane) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis analysis on 10 % gels. The separated proteins were
transferred onto polyvinylidene fluoride membranes
(Millipore, Temecula, CA, USA) using a semidry electro-
blotting system (Transblot SD; Bio-Rad). The blots were
incubated overnight at 4 °C in Tris-buffered saline with
Tween (TBST, 20 mmol/l Tris–HCl, pH 8.0, 150 mmol/l
NaCl, 0.5 % Tween-20) with 5 % nonfat dry milk contain-
ing the following primary antibodies: anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, rabbit monoclonal,
Cell Signaling Technology, Beverly, MA, USA; 1:2000),
anti-CD47 (rabbit polyclonal; GeneTex, Inc., San Antonio,
TX, USA; 1:500), anti-SIRP-α (rabbit polyclonal; GeneTex,
Inc., San Antonio, TX, USA; 1:1000), anti-CD200 (rabbit
polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA;
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1:500), and anti-CD200R (goat polyclonal; Santa Cruz Bio-
technology, Santa Cruz, CA; 1:500). After several washes
in TBST, the samples were incubated with a horseradish
peroxidase-conjugated goat anti-rabbit secondary anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA; 1:2000)
or donkey anti-goat secondary antibody (Santa Cruz Bio-
technology, Santa Cruz, CA; 1:2000) for 1 h at room
temperature. The antibodies were visualized using en-
hanced chemiluminescence. Immunoreactive bands were
analyzed densitometrically and normalized to GAPDH
using a Gel-Pro analyzer.
Immunohistochemistry and double-labeled
immunofluorescence
Six-micrometer-thick paraffin-embedded sections were
mounted on polylysine-coated slides and used for IHC.
The paraffin-embedded sections were de-paraffinized,
rehydrated, and incubated for 30 min in 0.3 % H2O2
diluted in methanol to quench endogenous peroxidase
activity. All of the samples were placed into phosphate
buffered saline (0.01 M, pH 7.3) and heated in a micro-
wave oven for antigen retrieval. The sections were then
incubated for 1 h at room temperature followed by incu-
bation with the following primary antibodies overnight
at 4 °C: anti-CD47 (rabbit polyclonal; GeneTex, Inc., San
Antonio, TX, USA; 1:100), anti-SIRP-α (rabbit poly-
clonal; GeneTex, Inc., San Antonio, TX, USA; 1:100),
anti-CD200 (rabbit polyclonal; Abcam, Cambridge, UK;
1:100), and anti-CD200R (rabbit polyclonal; ab198010,
Abcam, Cambridge, UK; 1:100). After three rinses, the
sections were incubated with the secondary goat anti-
rabbit immunoglobulin conjugated to peroxidase-labeled
dextran polymer (Envision + System-HRP; Boster, Wu-
han, China) for 1 h at 37 °C. The immunoreactions were
visualized using 3,3-diaminobenzidine (DAB; Boster,
Wuhan, China). The sections were counterstained with
hematoxylin, dehydrated, and coverslipped. No immuno-
reactive cells were detected in negative control experi-
ments, which included application of the secondary
antibody alone, preabsorption with a tenfold excess of a
specific blocking antigen or incubation with an isotype-
matched rabbit polyclonal antibody. Immunoreactivity
(IR) was observed under a Leica DMIRB microscope
(Leica, Nussloch, Germany).
For double-labeled immunofluorescence, sections were
incubated overnight at 4 °C with the following primary
antibodies: anti-CD47 (rabbit polyclonal; GeneTex, Inc.,
San Antonio, TX, USA; 1:100), anti-SIRP-α (rabbit poly-
clonal; GeneTex, Inc., San Antonio, TX, USA; 1:100), anti-
CD200 (rabbit polyclonal; Abcam, Cambridge, UK; 1:100),
and anti-CD200R (rabbit polyclonal; Abcam, Cambridge,
UK; 1:100), combined with anti-neurofilament (NF; mouse
monoclonal, Boster, Wuhan, China; 1:200), anti-glial fibril-
lary acidic protein (GFAP; mouse monoclonal, Sigma;
1:500), and anti-human leukocyte antigen-DR (HLA-DR;
mouse monoclonal, Dako, Denmark; 1:100). After three
washes, the sections were incubated with a mixture of
Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invi-
trogen; 1:500) and Alexa Fluor 594-conjugated goat
anti-mouse IgG (Invitrogen; 1:500) for 1 h at 37 °C.
4’,6-diamidino-2-phenylindole (DAPI, 10 μg/ml, Beyotime,
Nanjing, China) was used to counterstain the cell nuclei.
The fluorescent sections were visualized and photographed
with a laser scanning confocal microscope (TCS-TIV;
Leica, Nussloch, Germany).
Evaluation of immunoreactivity and cell counting
The evaluation of specific immunoreactivity, the pres-
ence or absence of various histopathological parameters,
and cell counting were assessed by two independent ob-
servers blind to clinical data. The overall concordance
was >90 %, and the overall kappa value ranged from 0.87
to 0.98. When a disagreement occurred, independent re-
evaluation was performed by both observers to define
the final score. A semi-quantitative analysis was per-
formed as previously described [38, 39]. Using a Leica
DMIRB microscope to examine a total microscopic area
of 781.250 μm2 (200 high-power non-overlapping fields
of 0.0625 × 0.0625 mm width, using a square grid
inserted into the eyepiece) in each section. The staining
intensity was evaluated using a semi-quantitative three-
point scale where the IR was defined as follows: − absent
(0), + weak (1), ++ moderate (2), and +++ strong stain-
ing (3). These scores represent the predominant staining
intensity in each section and were calculated as the aver-
age of the selected fields. In addition, we assessed the
number of positive cells within the cortical lesions of
FCD and TSC to obtain the relative proportion of im-
munoreactive cells. This frequency score was evaluated
by three distinct categories: (1) single to 10 %; (2) 11–50 %;
and (3) >50 %. The product of these two values (intensity
and frequency scores) was used to obtain the total score as
previously reported [13, 40].
To analyze the correlation between expression levels
(IR scores) of CD47, SIRP-α, and CD200 in FCD IIb and
TSC specimens and the number of activated microglia
labeled by HLA-DR [41], quantitative analysis was per-
formed as previously described [13, 42]. Images of two
representative fields per section (magnification 60 times)
were captured and digitized with a laser scanning con-
focal microscope (TCS-TIV; Leica, Nussloch, Germany).
The number of HLA-DR-positive cells was counted.
Cytokine ELISAs
Supernatants of the living cortical brain slices were
collected for ELISAs after 12 h of incubation, since the
viability of the slices in ACSF is still good at 12 h after
resection [43]. The concentrations of IL-1β (Bender
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MedSystems, Vienna, Austria), IL-6, and IL-17 (Pepro-
Tech, Rocky Hill, NJ, USA) were measured according to
the manufacturer’s instructions. ELISAs were performed
in duplicate, and the values were calculated from a
standard curve generated for each result. The data were
expressed in picogram per milliliter.
Statistical analyses
The data are expressed as the mean ± SD, and analysis was
performed using SPSS 19.0 package (SPSS Inc., Chicago, IL,
USA). Differences were assessed by the chi-square test for
gender and IR scores. And differences in age, epilepsy dur-
ation, seizure frequency, mRNA levels, and protein levels
were assessed by the Kruskal–Wallis test and Bonferroni
correction. Mann–Whitney U test was used for the com-
parison of cytokine concentrations. Spearman’s rank correl-
ation test was used for bivariate correlation analyses.
P < 0.05 was considered significant.
Results
Clinical variables and histological features
The clinical variables of all the subjects who were
enrolled in this study were summarized in Table 2.
There were no significant differences in gender and
age between the control subjects and epilepsy patients
(FCD IIb and TSC) (P > 0.05). Moreover, no significant
differences in gender, age, epilepsy duration, and seiz-
ure frequency were also found between FCD IIb and
TSC (P > 0.05).
The FCD subjects included displayed the histo-
pathological features of FCD IIb according to the
criteria of the ILAE, including the presence of dys-
morphic neurons and balloon cells (Additional file 1:
Figure S1B). As previously described, the histopatho-
logical features of the TSC cortical tubers include
cortical dyslamination, dysmorphic neurons, and
giant cells (Additional file 1: Figure S1C). Dys-
morphic neurons displayed large nucleoli, abnormal
soma size and orientation, and abundant Nissl sub-
stance staining. Balloon cells (giant cells in TSC)
were defined as morphologically abnormal cells with
a thin membrane, eosinophilic cytoplasm, and one or
more eccentrically located nuclei.
Quantitative real-time PCR analysis of CD47, SIRP-α,
CD200, and CD200R
Quantitative real-time PCR (qPCR) was employed to
qualify the messenger RNA (mRNA) levels of CD47,
Table 2 Clinical variables of the subjects in epilepsy groups and autopsy controls
Variable Control FCD IIb TSC P value
Number 6 12 13
Gender ratio (M/F) 3/3 5/7 6/7 P > 0.05a
Age 4.83 ± 3.47 5.12 ± 2.43 4.85 ± 2.24 P > 0.05b
Range 1.5–11 1.8–9.5 1.5–10
Epilepsy duration (year) NA 3.96 ± 2.16 3.76 ± 1.96 P > 0.05b
Range NA 1–8 0.9–8.1
Seizure frequency (per month) NA 60.00 ± 30.23 57.67 ± 28.82 P > 0.05b
Range NA 25-120 25–110
F female, M male, NA not applicable. Mean ± SD, P values calculated by achi-square test, bKruskal–Wallis test, Bonferroni correction
Fig. 1 Messenger RNA expression of CD47, SIRP-α, CD200, and
CD200R in control, FCD IIb, and TSC specimens. Quantitative real-time
PCR analysis showed that the mRNA levels of CD47 (a) and its receptor
SIRP-α (a) and CD200 (b) were significantly decreased in FCD IIb and
TSC compared with control specimens, while CD200R (b) mRNA level
was not significantly changed. There were no significant differences in
CD47, CD200, and their receptors between FCD IIb and TSC specimens.
The bar charts represent mean ± SD, *P < 0.05, FCD IIb, TSC versus
controls, Kruskal–Wallis test, and Bonferroni correction
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SIRP-α, CD200, and CD200R in the total homogenates
from FCD IIb cortical lesions, TSC cortical tubers, and
control tissues, with β-actin as an internal control. De-
creased mRNA expression of CD47, SIRP-α, and CD200
were observed in both the FCD IIb and TSC lesions
compared with control tissues (P < 0.05; Fig. 1a, b),
whereas the CD200R mRNA level was not significantly
changed (P > 0.05; Fig. 1b).
Western blot analysis of CD47, SIRP-α, CD200, and
CD200R
We used western blot to examine the protein levels
of CD47, SIRP-α, CD200, and CD200R in the total
homogenates from FCD IIb cortical lesions, TSC cor-
tical tubers, and control tissues, with GAPDH as an
internal control. Similar to that in mRNA expression,
the protein levels of CD47, SIRP-α, and CD200 were
downregulated in both the FCD IIb and TSC lesions
compared with control tissues (P < 0.05; Fig. 2a–d),
while the CD200R protein level was not significantly
altered (P > 0.05; Fig. 2c, d).
Immunohistochemistry analysis of CD47, SIRP-α, CD200,
and CD200R
CD47
Histologically normal autopsy cortex displayed strong som-
atic CD47 IR in pyramidal neurons (Fig. 3a) and showed
moderate and sporadic CD47 IR in glial cells within white
matter (Fig. 3b). In FCD IIb and TSC specimens, weak or
undetectable CD47 IR was observed in dysmorphic neurons
(Fig. 3c, e). Weak or undetectable CD47 IR was also de-
tected in balloon cells of FCD IIb and in giant cells of TSC
(Fig. 3d, f, and g). The CD47 IR score was significantly de-
creased in both the FCD IIb and TSC specimens compared
with the controls (P < 0.05; Fig. 4a) and showed significant
negative correlation with the number of HLA-DR-positive
cells in FCD IIb (Fig. 5a) and TSC (Fig. 5d). Double labeling
demonstrated the co-localization of CD47 IR with NF in
certain dysmorphic neurons and giant cells (Fig. 3h, k) and
with HLA-DR in certain microglia (Fig. 3j, m). GFAP-
positive astrocytes did not display CD47 IR (Fig. 3i, l).
SIRP-α
In histologically normal autopsy specimens, SIRP-α
strongly expressed in pyramidal neurons within cortex
(Fig. 6a) and showed moderate IR in glial cells within
white matter (Fig. 6b). FCD IIb and TSC specimens
displayed weak or undetectable SIRP-α IR in dys-
morphic neurons (Fig. 6c, e). Balloon cells of FCD IIb
and giant cells of TSC did not exhibit detectable SIRP-
α IR (Fig. 6d, f ). The IR score of SIRP-α was dramatic-
ally lower in both the FCD IIb and TSC specimens
than that in controls (P < 0.05; Fig. 4b) but showed no
significant correlation with the number of HLA-DR-
positive cells in FCD IIb (Fig. 5b) and TSC (Fig. 5e).
Double labeling demonstrated the co-expression of
Fig. 2 Protein expression of CD47, SIRP-α, CD200, and CD200R in control, FCD IIb, and TSC specimens. a, c Representative immunoblot of CD47,
CD200 and their receptors in control, FCDIIb and TSC samples. Expression of GAPDH (as reference protein) is shown in the same protein extracts.
Densitometric analysis of western blot showed that CD47 (b), SIRP-α (b), and CD200 (d) protein levels were significantly decreased in FCD IIb and
TSC compared with the control specimens, while CD200R (d) protein level was not significantly changed. There were no significant differences in
CD47, SIRP-α, CD200, and CD200R between FCD IIb and TSC specimens. The bar charts represent mean ± SD, *P < 0.05, FCD IIb, TSC versus controls,
Kruskal–Wallis test and Bonferroni correction
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SIRP-α IR with NF in some dysmorphic neurons and giant
cells (Fig. 6g, j) and with HLA-DR in certain microglia
(Fig. 6i, l), whereas the absence of SIRP-α IR was observed
in GFAP-positive astrocytes (Fig. 6h, k).
CD200
In histologically normal autopsy specimens, moderate to
strong CD200 IR was observed in pyramidal neurons
within cortex (Fig. 7a). Weak and sporadic CD200 IR was
detected within white matter (Fig. 7b). In FCD IIb and TSC
specimens, weak CD200 IR was observed in dysmorphic
neurons (Fig. 7c, e). Weak CD200 IR was also detected in
balloon cells of FCD IIb (Fig. 7d). Giant cells of TSC exhib-
ited weak or undetectable CD200 IR (Fig. 7f). The IR score
of CD200 was significantly downregulated in both FCD
IIb and TSC specimens versus the controls (P < 0.05;
Fig. 4c) and showed significant negative correlation with
the number of HLA-DR-positive cells in FCD IIb (Fig. 5c)
and TSC (Fig. 5f). Double labeling showed that CD200 IR
was co-localized with NF and GFAP in certain dysmorphic
Fig. 3 CD47 IR in control, FCD IIb, and TSC specimens. a, b CD47 IR in control specimens. a Strong somatic staining of CD47 in neurons (arrows
and inset) within cortex. b Sporadic CD47 IR in glial cells (arrowheads) within white matter and co-localization of CD47 (green) and HLA-DR (red) in
a microglia (inset). c, d CD47 IR in cortical lesions of FCD IIb. c Weak CD47 IR in dysmorphic neurons (arrows). d Negative balloon cells (arrowheads
and inset) and weak CD47 IR in balloon cells (arrows). e–g CD47 IR in cortical tubers of TSC. e Negative dysmorphic neurons (arrowheads) and weak to
moderate staining in dysmorphic neurons (arrows). f Weak CD47 IR in giant cells (arrows) and in a glial cell (arrowhead). g High magnification showing a
giant cell with weak CD47 IR. h–j Double labeling in cortical lesions of FCDIIb specimens. h Co-localization of CD47 (green) with NF (red) in dysmorphic
neurons. i Absence of co-localization between CD47 (green) and GFAP (red) in astrocytes (arrows: astrocytes, arrowhead: dysmorphic neuron). j
Co-localization of CD47 (green) and HLA-DR (red) in a microglia (arrow; arrowhead: dysmorphic neuron). k–m Double labeling in cortical tubers
of TSC specimens. k Co-localization of CD47 (green) with NF (red) in giant cells. l Absence of co-localization between CD47 (green) and GFAP (red) in
astrocytes (arrows: astrocytes, arrowhead: giant cell).m Co-localization of CD47 (green) and HLA-DR (red) in microglia (arrows; arrowhead: giant cell).
Scale bars: a 40 μm; b 35 μm; d, e: 50 μm; f 30 μm, g 20 μm; h–m 50 μm
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neurons, giant cells, and reactive astrocytes (Fig. 7g, h, j,
and k). HLA-DR-positive microglia did not express
CD200 (Fig. 7i, l).
CD200R
In histologically normal autopsy specimens, we did
not detect CD200R IR in neurons within the cortex
but observed weak and sporadic IR in glial cells
within white matter (Fig. 8a, b). In FCD IIb and TSC
specimens, CD200 IR was not observed in dys-
morphic neurons (Fig. 8c, e), balloon cells (Fig. 8d),
or giant cells (Fig. 8f ) but was detected in certain
glial cells with weak IR (Fig. 8d, f ). The IR score of
CD200R was not significantly changed in both the
FCD IIb and TSC specimens compared with the con-
trols (P > 0.05; Fig. 4d). Double labeling showed that
CD200R IR was co-localized with HLA-DR in certain
microglia (Fig. 8g–l).
Effects of soluble human recombinant CD47 Fc and
CD200 Fc on the production of IL-1β, IL-6, and IL-17
The concentration of cytokines was measured by ELI-
SAs. Both CD47 Fc and CD200 Fc could reduce the IL-6
production (P < 0.05; Fig. 9c, d). Interestingly, IL-1β and
IL-17 that were closely associated with IL-6 in
epileptogenic lesions of MCD were not suppressed by
CD47 Fc (P > 0.05; Fig. 9a, b) or CD200 Fc (P > 0.05;
Fig. 9e, f ).
IL-4 mRNA expression and its correlation with CD200
mRNA level
Previous studies showed that IL-4 and IL-13 increase
the expression of CD200/CD200R [31, 32], so we investi-
gated the mRNA expression of IL-4 and IL-13 in con-
trol, FCD IIb, and TSC specimens and the correlations
with CD200 level. Quantitative real-time PCR analysis
showed that IL-4 mRNA level was significantly de-
creased in FCD IIb and TSC compared with control
specimens (P < 0.05; Fig. 10a). Scatter plot showing the
significant positive correlation between IL-4 and CD200
mRNA levels in FCD IIb (P < 0.05, r = 0.79; Fig. 10b) and
TSC (P < 0.01, r = 0.82; Fig. 10c). Consistent with a pre-
vious study [32], we fail to detect IL-13 expression in
our study (data not shown).
Discussion
In the present study, we demonstrate that the expression
of the immune inhibitory molecules CD47 and its recep-
tor, SIRP-α, and CD200 are downregulated in surgically
resected brain tissues from patients with FCD IIb and
TSC, both of which are associated with medically
Fig. 4 Semi-quantitative evaluation of CD47, SIRP-α, CD200, and CD200R IR scores (total score; for details refer to “Methods” section) in control,
FCDIIb, and TSC specimens. IR scores of CD47 (a), SIRP-α (b), and CD200 (c) in FCD IIb and TSC specimens were decreased compared with those
in controls, P < 0.05, chi-square test; whereas IR score of CD200R (d) was not altered, P > 0.05, chi-square test. There were no significant differences
in IR scores of CD47, SIRP-α, CD200, and CD200R between FCD IIb and TSC specimens. P > 0.05, chi-square test
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intractable pediatric epilepsy, whereas the expression of
CD200 receptor, CD200R, is not significantly altered. In
addition, we show that both soluble human recombinant
CD47 Fc and CD200 Fc could reduce IL-6 release in the
living epileptogenic brain slices FCD IIb and TSC pa-
tients in vitro. These findings provide evidence of an im-
mune inhibitory deficit involving CD47/SIRP-α and
CD200/CD200R pathways in human epileptogenic le-
sions of FCD IIb and TSC patients.
CD47 is ubiquitously expressed in various resident
cells of the CNS, transducing an inhibitory signal via its
receptor, SIRP-α, which is present on microglia/macro-
phages and neurons. It was reported that CD47 expression
is decreased in human brain lesions of multiple sclerosis
(MS), a CNS autoimmune neuroinflammatory disease,
whereas SIRP-α expression is unchanged, suggesting that
decreased CD47 expression contribute to a disturbed
equilibrium in macrophage and microglia activation in
MS lesions and may result in a proinflammatory predis-
position in the area surrounding chronic active lesions
[44]. Han et al. further demonstrated that CD47 is
expressed in normal myelin and in foamy macrophages
and reactive astrocytes within active MS lesions (not in
reactive astrocytes within chronic MS lesions) and dis-
plays Janus-like opposing effects on MS pathogenesis
by interacting with SIRP-α, which is likely caused by
Fig. 5 Correlation between IR scores (relative expression levels) of CD47, SIRP-α, CD200, and the number of HLA-DR-positive cells (activated microglia).
a Scatter plot showing the significant negative correlation between the IR score of CD47 and the number of HLA-DR-positive cells in FCD IIb (P < 0.05,
r = −0.74). b No significant correlation between the IR score of SIRP-α and the number of HLA-DR-positive cells in FCD IIb (P > 0.05, r = −0.31).
c Significant negative correlation between the IR score of CD200 and the number of HLA-DR-positive cells in FCD IIb (P < 0.05, r = −0.78). d Scatter plot
showing the significant negative correlation between the IR score of CD47 and the number of HLA-DR-positive cells in TSC (P < 0.05, r = −0.75). e No
significant correlation between the IR score of SIRP-α and the number of HLA-DR-positive cells in TSC (P > 0.05, r = 0.48). f Significant negative
correlation between the IR score of CD200 and the number of HLA-DR-positive cells in FCD IIb (P < 0.05, r = −0.71). Correlation analysis performed with
Spearman’s rank correlation coefficient
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the expression of CD47 in different cell types and loca-
tions [45].
Our results showed that the expression of CD47 was
downregulated at both the messenger RNA and protein
levels in epileptogenic lesions of FCD IIb and TSC and
that the SIRP-α expression was also decreased, which is
different from what has been observed in human MS. In
the control specimens, CD47 and SIRP-α were relatively
Fig. 6 SIRP-α IR in control, FCD IIb, and TSC specimens. a, b SIRP-α IR in control specimens. a Strong somatic SIRP-α IR in neurons (arrows) within cortex.
b Moderate SIRP-α IR in glial cells (arrowheads) within white matter and co-localization of SIRP-α (green) and HLA-DR (red) in a microglia (inset). c, d SIRP-α
IR in cortical lesions of FCD IIb specimens. c Weak SIRP-α IR was occasionally detected in some dysmorphic neurons (arrows). d Negative balloon cells
(arrowheads). e, f SIRP-α IR in cortical tubers of TSC specimens. e Weak SIRP-α IR in dysmorphic neurons (arrows) and a negative dysmorphic neurons
(arrowheads). f Negative giant cells (arrowheads). g–i Double labeling in cortical lesions of FCD IIb specimens. g Co-localization of SIRP-α
(green) with NF (red) in some dysmorphic neurons (arrows). h Absence of co-localization between SIRP-α (green) and GFAP (red) in astrocytes
(arrows: astrocytes, arrowhead: dysmorphic neuron). i Co-localization of SIRP-α (green) with HLA-DR (red) in microglia (arrow). j–l Double labeling in cortical
tubers of TSC specimens. j Absence of co-localization between SIRP-α (green) and NF (red) in giant cells (arrowheads). k Absence of co-localization
between SIRP-α (green) and GFAP (red) in astrocytes (arrows: astrocytes, arrowhead: giant cell). l Co-localization of SIRP-α (green) with HLA-DR
(red) in microglia (arrow). Scale bars: a 30 μm; b, e = 50 μm; c 35 μm; d 35 μm; f 30 μm; g, h, j, and k 50 μm; i, l 25 μm
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highly expressed in neurons but expressed at lower
levels in dysmorphic neurons, balloon cells, and giant
cells in epileptogenic lesions of FCD IIb and TSC pa-
tients. In addition, weak to moderate CD47 and SIRP-α
IR were detected in certain microglia in both control
and epileptogenic lesions, which is in agreement with
previous studies showing that both CD47 and SIRP-α
are expressed in cultured microglia [19, 22]. Moreover,
Fig. 7 CD200 IR in control, FCD IIb, and TSC specimens. a, b CD200 IR in control specimens. a Moderate to strong somatic CD200 IR in neurons
(arrows and inset) within cortex. b Weak CD200 IR in white matter (arrowheads). c, d CD200 IR in cortical lesions of FCD IIb specimens. c Weak
CD200 IR in dysmorphic neurons (arrows). d Weak CD200 IR in balloon cells (arrows). e, f CD200 IR in cortical tubers of TSC specimens. e Weak
CD200 IR in dysmorphic neurons (arrows and inset). f Weak CD200 IR in a giant cell (inset) and negative giant cells (arrowheads). g–i Double
labeling in cortical lesions of FCD IIb specimens. g Co-localization of CD200 (green) with NF (red) in dysmorphic neurons (arrows). h Co-localization of
CD200 (green) with GFAP (red) in reactive astrocytes (arrows: astrocytes, arrowhead: dysmorphic neuron). i Absence of co-localization between CD200
(green) with HLA-DR (red) in microglia (arrow: microglia, arrowhead: dysmorphic neuron). j–l Double labeling in cortical tubers of TSC
specimens. j Co-localization of CD200 (green) and NF (red) in certain giant cell (arrow). k Co-localization of CD200 (green) with GFAP
(red) in reactive astrocytes (arrows: astrocytes, arrowhead: giant cell). l Absence of co-localization between CD200 (green) and HLA-DR
(red) in microglia (arrows: microglia, arrowhead: giant cell). Scale bars: a 30 μm; b–l 50 μm
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significant negative correlation between the IR score of
CD47 and the number of HLA-DR-positive cells, repre-
senting activated microglia [41], was observed in FCD
IIb and TSC specimens. These findings indicate an inef-
ficient combination of CD47 and SIRP-α not only in
neuron-neuron interactions but also in neuron-microglia
interactions. On the one hand, neuronal CD47/SIRP-α
complex has been demonstrated to play important roles
in neuronal network formation, as evident by the ob-
servation that CD47/SIRP-α is able to promote neurite
Fig. 8 CD200R IR in control, FCD IIb, and TSC specimens. a, b CD200R IR in control specimens. a Undetectable CD200 IR in neurons (arrows and
inset) within cortex. b Weak and sporadic CD200R IR in white matter (arrowheads) and co-localization of CD200R (green) and HLA-DR (red) in a
microglia (inset). c, d CD200 IR in cortical lesions of FCD IIb specimens. c CD200R IR was not observed in dysmorphic neurons (arrowheads).
d CD200R IR was not found in balloon cells (arrows) but was detected in certain glial cells (arrowheads). e, f CD200R IR in cortical tubers of
TSC specimens. e Negative dysmorphic neurons (arrowheads). f Weak CD200R IR in glial cells (arrowheads) and negative giant cells (arrows).
g–i Double labeling in cortical lesions of FCD IIb specimens shows co-localization of CD200R (green) with HLA-DR (red) in microglia (arrow).
j–l Double labeling in cortical tubers of TSC specimens shows co-localization of CD200R (green) with HLA-DR (red) in microglia (arrow).
Scale bars: a–c, e–f 50 μm; d 40 μm; g–l 35 μm
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and dendritic spine formation in cultured hippocampal
neurons [46, 47]. Thus, CD47-SIRP-α deficiency in the
misshapen cells (e.g., dysmorphic neurons, balloon cells,
giant cells) within the epileptogenic lesions might contrib-
ute to the abnormal neuronal migration and differenti-
ation during brain development in FCD IIb and TSC
patients [48, 49]. On the other hand, since the interaction
between neuronal CD47 and microglial SIRP-α results in
the inhibition of microglia [50], the inefficient CD47/
SIRP-α interaction between misshapen cells and microglia
within the epileptogenic lesions may conduce to micro-
glial activation, which abundantly occurs in epileptogenic
lesions of FCD IIb and TSC and is thought to perpetuate
and prolong the inflammation [41, 51–53]. However, the
specific roles of CD47/SIRP-α in these processes of FCD
IIb and TSC require further investigation. Although CD47
and SIRP-α were found to be expressed in microglia in
both control and epileptogenic lesions of FCD IIb and
TSC, the role of CD47/SIRP-α interaction in microglia is
still under investigation [22].
Similar to CD47/SIRP-α, CD200/CD200R is another anti-
inflammatory system in the brain. CD200 is broadly
expressed on neurons and other cells and mediates inhibi-
tory signals via its receptor, CD200R, on cells of the myeloid
lineage, including macrophage/microglia. A previous study
demonstrated that CD200-deficient mice exhibit an in-
creased number of microglia/macrophages with a more acti-
vated phenotype, as well as an accelerated and aggravated
course of EAE [28]. Conversely, mice with elevated neuronal
expression of CD200 due to a mutation in the Wlds gene
display an attenuated EAE course with decreased CNS
macrophage/microglial accumulation [54]. Moreover, the
level of CD200, together with its receptor, CD200R, has
been reported to be decreased in Alzheimer’s disease (AD),
a neurodegenerative disease, that is characterized by on-
going chronic inflammation in the brain lesions [32, 55].
Fig. 9 Effects of soluble recombinant human CD47 Fc Chimera protein and CD200 Fc chimera protein on the production of IL-1β, IL-6, and IL-17,
as measured by ELISAs. IL-1β release was not inhibited by CD47 Fc (a) or CD200 Fc (b). Both CD47 Fc (c) and CD200 Fc (d) reduced the IL-6
production. The IL-17 release was not suppressed by CD47 Fc (e) or CD200 Fc (f). These data are representative of four experiments. The bar
charts represent mean ± SD, Mann–Whitney U test, *P < 0.05
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In the present study, we provided the first evidence of
cell-specific downregulation of both mRNA and protein
levels of CD200 in epileptogenic lesions of FCD IIb and
TSC patients, while the expression of its receptor,
CD200R, was not significantly changed. Accordingly,
similar alterations in its expression have been reported
in human MS brain lesions [44]. Immunohistochemical
analysis showed that CD200 was consistently and pre-
dominantly expressed in neurons within histologically
normal cortex, while its expression was dramatically de-
creased in misshapen cells in epileptogenic lesions of
FCD IIb and TSC patients, including dysmorphic neu-
rons, balloon cells, and giant cells. We did not observe
CD200R expression in neurons of the control specimens
or in misshapen cells within epileptogenic tissues, but
we detected CD200R expression in some microglia in
both control specimens and epileptogenic lesions of
FCD IIb and TSC patients. Additionally, CD200 IR score
displayed significant negative correlation with the num-
ber of HLA-DR-positive cells (activated microglia) in
FCD IIb and TSC specimens. It is hypothesized that the
decreased expression of CD200 in these misshapen cells
may lead to the inefficient interaction between CD200
and CD200R, which subsequently contributes to micro-
glial activation and the concomitant chronic inflammation
in epileptogenic lesions of FCD IIb and TSC patients.
In addition to its localization to neurons, CD200 expres-
sion has also been observed in reactive astrocytes within
brain lesions of human MS and AD patients [32, 56]. In
agreement, we also detected weak and sporadic expression
of CD200 in reactive astrocytes that were abundantly
present in the epileptogenic lesions of MCD [57]. This sug-
gests that CD200-mediated immune suppression might
also occur through astrocyte-microglia interactions during
the inflammatory epileptogenic lesions of FCD IIb and
TSC. However, the evaluation of CD200 function in
reactive astrocytes needs to be further investigated.
Evidence has recently been presented showing inflamma-
tory response markers in developing cortical tubers of fetal
TSC brain ranging from 23 to 38 gestational weeks, includ-
ing major histocompatability complexes classes I and II,
Toll-like receptors 2 and 4, and receptor for advanced glyca-
tion end products [58]. These findings are relevant and sig-
nificant in demonstrating that at least some inflammation in
tuberous sclerosis begin very early and thus may be an inte-
gral part of pathogenesis, not just a reactive change to it.
Previous studies have revealed that many proinflamma-
tory cytokines are upregulated in epileptogenic lesions and
play pivotal roles in the epileptogenesis of FCD IIb and
TSC patients, including IL1-β, IL-6, and IL-17 [15–17, 30].
It has been demonstrated that CD47 Fc could decrease pro-
inflammatory cytokine release, including IL-6, IL-12, tumor
necrosis factor α, and interferon-γ, by binding to its recep-
tor, SIRP-α, in human dendritic cells [24]. CD200 Fc has
also been reported to suppress IL-6 and IL1-β production
by engaging CD200R in activated microglia [36].
In our in vitro assay, we showed that soluble human re-
combinant CD47 Fc and CD200 Fc could reduce IL-6 re-
lease but did not suppress IL1-β or IL-17 production, in
living cortical brain slices from patients with FCD IIb and
TSC. Therefore, we speculate that CD47 and CD200 exert
an anti-inflammatory function in epileptogenic lesions of
FCD IIb and TSC by suppressing the production of
Fig. 10 IL-4 mRNA expression in control, FCD IIb, and TSC specimens
and the correlation between IL-4 and CD200 mRNA levels in FCD IIb
and TSC specimens. a Quantitative real-time PCR analysis showed that
IL-4 mRNA level was significantly decreased in FCD IIb and TSC
compared with control specimens. There was no significant difference
in IL-4 mRNA expression between FCD IIb and TSC specimens. The bar
charts represent mean ± SD, *P < 0.05, FCD IIb, TSC versus controls,
Kruskal–Wallis test, and Bonferroni correction. Scatter plot showing the
significant positive correlation between IL-4 and CD200 mRNA levels in
FCD IIb (b) (P < 0.05, r = 0.79) and TSC (c) (P < 0.01, r = 0.82). Correlation
analysis performed with Spearman’s rank correlation coefficient
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proinflammatory cytokines, such as IL-6, but the mechan-
ism requires further exploration. Due to the limited amount
of human samples, we did not examine the effect of CD47
Fc and CD200 Fc on the inhibition of these proinflammatory
cytokines at different doses and time points.
It has been demonstrated that IL-4 markedly increases
CD200 expression in cultured hippocampal neurons and
that CD200 staining was significantly decreased in neu-
rons prepared from IL-4 knockout mice compared with
wild-type ones [31]. IL-4 has also been shown to upregu-
late CD200R expression in human microglia and micro-
phages [32]. In this study, we showed that IL-4 mRNA
level was significantly decreased in FCD IIb and TSC
specimens compared with the control samples and dis-
played positive correlation with CD200 mRNA level. Since
IL-4 is a well-recognized anti-inflammatory cytokine [59],
our findings are suggestive that in epileptogenic lesions of
FCD IIb and TSC, anti-inflammatory cytokines like IL-4
are deficient and that decreased expression of CD200 may
be partially caused by insufficient IL-4 level.
Conclusions
In this study, we have described reduced expression of
CD47/SIRP-α and CD200 in epileptogenic brain tissues
from patients with FCD IIb and TSC, while CD200R expres-
sion is unchanged. Our results suggest that microglial acti-
vation may be partially caused by CD47/SIRP-α- and
CD200/CD200R-mediated reductions in the immune inhibi-
tory pathways within FCD IIb and TSC cortical lesions
where chronic neuroinflammation has been established. Up-
regulation or activation of CD47/SIRP-α and CD200/
CD200R has been demonstrated to be beneficial in several
immune inflammatory disease models. We speculate that
increasing CD47/SIRP-α and CD200/CD200R expression
may also have protective roles in FCD IIb and TSC, since
we have revealed that CD47 Fc and CD200 Fc could reduce
IL-6 release, a key proinflammatory cytokine involved in
FCD IIb and TSC. However, due to the limitation of studies
using human samples and the absence of genuine models of
FCD IIb and TSC [60], the evidence we provide here is
largely descriptive. More functional studies are needed to
explore the inherent role of CD47/SIRP-α and CD200/
CD200R pathways in epileptogenesis of MCD, as well as
possible therapeutic interventions based on the regulation of
the these two systems.
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neurons (arrows) and balloon cells (arrowheads). (c) Dysplastic area of
TSC, dysmorphic neurons (arrows) and giant cells (arrowheads). Scale
bars: 100 μm for all panels. (TIF 4.12 mb)
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